Company profile

Greenwich LifeSciences, Inc.

Pipeline1 asset

GLSI-100GP2 + GM-CSF / HER2/neu / peptide immunotherapy vaccine / Oncology
Prevention of recurrence in HER2/neu-positive breast cancer after surgery and trastuzumab-based therapyPhase 3Ongoing; Fast Track designated; FLAMINGO-01United StatesEurope

Latest news12 items

May 22, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Apr 30, 2026

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Interim Data • Phase 3

Apr 23, 2026

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Presentation / Abstract • Phase 3

Apr 22, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 20, 2026

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Presentation / Abstract • Phase 3

Apr 14, 2026

Greenwich LifeSciences Provides Update on Financing Strategy

Apr 7, 2026

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Mar 19, 2026

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Mar 18, 2026

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Presentation / Abstract • Phase 3

Mar 17, 2026

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Interim Data • Phase 3

Mar 16, 2026

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Mar 3, 2026

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Greenwich LifeSciences, Inc. • Endpoint Arena